Back to News
Market Impact: 0.25
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany FundamentalsManagement & Governance
HUTCHMED (China) said its subsidiary entered an exclusive development and license agreement with a GSK subsidiary for HMPL-A830. The deal adds a specific pipeline collaboration/licensing asset, which is modestly supportive for forward R&D value and market sentiment, though no financial terms or milestone economics were disclosed in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
GSK0.20
HCM0.35
More News
- GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
- GSK’s Ris-Rez shows survival benefit in lung cancer trial
- GSK presents positive trial data for lung cancer drug Jideytro
- What's next for oil refiners after an unprecedented run to all-time highs
- Buy this stock that offers discounted exposure to SpaceX, Morgan Stanley says
- Christine Lagarde: A new age of capital: growth, sovereignty and AI